This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas | MicrobiomeTrials
← Back to trials NCT03220022
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2018-03-16Est. Completion: 2024-10-10
Enrollment target: 46 participantsLocations UC San Diego Moores Cancer Center, La Jolla, California, United States UCSF Medical Center-Parnassus, San Francisco, California, United States University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States Memorial Hospital West, Pembroke Pines, Florida, United States John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States Boston Medical Center, Boston, Massachusetts, United States Siteman Cancer Center at Washington University, St Louis, Missouri, United States Washington University School of Medicine, St Louis, Missouri, United States Mount Sinai Hospital, New York, New York, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States Montefiore Medical Center - Moses Campus, The Bronx, New York, United States Memorial Sloan Kettering Nassau, Uniondale, New York, United States Other microbiome trials you might be interested in KSHV Inflammatory Cytokine Syndrome (KICS) KSHV HHV-8
Background:
\- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associ…
Bethesda, United States Est. completion Dec 31, 2028
ALK-Positive Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Activated B-Cell Type Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Virginia Mason Medical Center, Seattle, Washington, United States Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
EBV-Positive Mucocutaneous Ulcer
HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Intravascular Large B-Cell Lymphoma
Large B-Cell Lymphoma With 11q Aberration
Large B-Cell Lymphoma With IRF4 Rearrangement
Plasmablastic Lymphoma
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Primary Effusion Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Burkitt Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Gray-Zone Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent Lymphomatoid Granulomatosis
Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Burkitt Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Gray-Zone Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-c…
Phoenix, United States Est. completion May 26, 2023
Charcot Joint of Foot Osteoarthropathy
Charcot foot, characterized by progressive destructive damage to bone, soft tissue and tendons, involving joint dislocat…
Boulogne-sur-Mer, France Est. completion Jul 22, 2027